Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AlconALC -0.51%71 EV-to-EBITDA is 14.87 as of Jul. 19, 2026, which is 36% below its 10-year median of 23.18. GuruFocus rates ALC with a GF Score™ of 71/100 and a GF Value™ of $93.53 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 510 Medical Devices & Instruments companies, Alcon ranks worse than 54.51% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Alcon's enterprise value is $37,766 Mil.
Alcon's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $2,540 Mil. Therefore, Alcon's EV-to-EBITDA for today is 14.87.
The historical rank and industry rank for Alcon's EV-to-EBITDA or its related term are showing as below:
ALC'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -678.63 Med: 23.18 Max: 140.5
Current: 15.07
During the past 10 years, the highest EV-to-EBITDA of Alcon was 140.50. The lowest was -678.63. And the median was 23.18.
ALC's EV-to-EBITDA is ranked worse than 54.51% of 510
companies
in the Medical Devices & Instruments industry
Industry Median: 14.155
vs ALC: 15.07
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2026-07-19), Alcon's stock price is $70.26.
Alcon's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $1.660. Therefore, Alcon's PE Ratio (TTM) for today is 42.33.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Alcon (NYSE:ALC) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Alcon's share price for today is $70.26.
Alcon's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.660.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Alcon's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Alcon's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alcon EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Alcon's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Alcon's EV-to-EBITDA falls into.
Alcon's current Enterprise Value is $37,766 Mil.
Alcon's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2,540 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alcon (ALC) has a EV-to-EBITDA of 14.87 as of Jul. 19, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Alcon. This is 36% below median its historical median of 23.18. According to the industry distribution chart, Alcon ranks #278 out of 510 companies in the Medical Devices & Instruments industry, placing it in the top 54.5%.
Is Alcon's EV-to-EBITDA too high?
Alcon's current EV-to-EBITDA of 14.87 is 36% below median its 10-year median of 23.18. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.16. Alcon's value of 14.87 is 5.1% above this industry median. Based on the distribution chart, Alcon ranks #278 out of 510 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Alcon has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alcon's EV-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Alcon ranks #278 out of 510 companies for EV-to-EBITDA. This places Alcon in the lower half of its industry. The industry median EV-to-EBITDA is 14.16. Alcon's value of 14.87 is 5.1% above this benchmark. While the company's 10-year median is 23.18 vs. the industry median of 14.16, Alcon has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.16, based on 510 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alcon's current EV-to-EBITDA of 14.87 is 5.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Alcon. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alcon's current EV-to-EBITDA is 14.87, which is 36% below median its own 10-year median of 23.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alcon stock overvalued right now?
Based on GuruFocus' analysis, Alcon (ALC) is currently considered Modestly Undervalued. The stock's GF Value™ is $93.53, compared to a current price of $70.26 — trading 24.9% below its estimated fair value. The current EV-to-EBITDA is 14.87, which is 36% below median its 10-year median of 23.18 and 5.1% above the Medical Devices & Instruments industry median of 14.16. Alcon's overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Alcon (ALC), the current EV-to-EBITDA is 14.87 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alcon (ALC) Overvalued in 2026?
Based on GuruFocus' analysis, Alcon stock appears to be undervalued.
The current stock price of $70.26 is trading 24.9% below its estimated GF Value™ of $93.53.
GuruFocus considers Alcon to be Modestly Undervalued.
Key valuation signals for ALC:
EV-to-EBITDA: 14.87 (36% below median its 10-year median of 23.18)
GF Value™: $93.53 vs. price of $70.26 (24.9% below fair value)
Industry Position: 5.1% above the Medical Devices & Instruments median (#278 of 510)
No single metric tells the full story. See the ALC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.
71GF Score
Get the complete analysis for ALC
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALC has been successfully added to your 
